vs
Eventbrite, Inc.（EB）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
Eventbrite, Inc.的季度营收约是RHYTHM PHARMACEUTICALS, INC.的1.3倍（$73.5M vs $57.3M），Eventbrite, Inc.净利率更高（-11.1% vs -83.0%，领先71.9%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（36.9% vs -3.9%），过去两年RHYTHM PHARMACEUTICALS, INC.的营收复合增速更高（48.5% vs -7.7%）
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
EB vs RYTM — 直观对比
营收规模更大
EB
是对方的1.3倍
$57.3M
营收增速更快
RYTM
高出40.7%
-3.9%
净利率更高
EB
高出71.9%
-83.0%
两年增速更快
RYTM
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.5M | $57.3M |
| 净利润 | $-8.2M | $-47.5M |
| 毛利率 | 68.1% | 91.6% |
| 营业利润率 | -12.4% | -82.2% |
| 净利率 | -11.1% | -83.0% |
| 营收同比 | -3.9% | 36.9% |
| 净利润同比 | 2.5% | -9.6% |
| 每股收益（稀释后） | $-0.08 | $-0.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBRYTM
| Q4 25 | $73.5M | $57.3M | ||
| Q3 25 | $71.7M | $51.3M | ||
| Q2 25 | $72.8M | $48.5M | ||
| Q1 25 | $73.8M | $32.7M | ||
| Q4 24 | $76.5M | $41.8M | ||
| Q3 24 | $77.8M | $33.3M | ||
| Q2 24 | $84.6M | $29.1M | ||
| Q1 24 | $86.3M | $26.0M |
净利润EBRYTM
| Q4 25 | $-8.2M | $-47.5M | ||
| Q3 25 | $6.4M | $-52.9M | ||
| Q2 25 | $-2.1M | $-46.6M | ||
| Q1 25 | $-6.6M | $-49.5M | ||
| Q4 24 | $-8.4M | $-43.3M | ||
| Q3 24 | $-3.8M | $-43.6M | ||
| Q2 24 | $1.1M | $-32.3M | ||
| Q1 24 | $-4.5M | $-141.4M |
毛利率EBRYTM
| Q4 25 | 68.1% | 91.6% | ||
| Q3 25 | 67.9% | 89.3% | ||
| Q2 25 | 67.5% | 88.6% | ||
| Q1 25 | 66.9% | 88.8% | ||
| Q4 24 | 68.2% | 90.9% | ||
| Q3 24 | 68.5% | 88.5% | ||
| Q2 24 | 70.9% | 89.9% | ||
| Q1 24 | 71.0% | 89.2% |
营业利润率EBRYTM
| Q4 25 | -12.4% | -82.2% | ||
| Q3 25 | -1.3% | -102.6% | ||
| Q2 25 | -8.7% | -93.4% | ||
| Q1 25 | -13.2% | -143.7% | ||
| Q4 24 | -10.2% | -98.6% | ||
| Q3 24 | -11.5% | -132.0% | ||
| Q2 24 | -7.6% | -139.2% | ||
| Q1 24 | -8.8% | -538.7% |
净利率EBRYTM
| Q4 25 | -11.1% | -83.0% | ||
| Q3 25 | 8.9% | -103.1% | ||
| Q2 25 | -2.9% | -96.1% | ||
| Q1 25 | -9.0% | -151.4% | ||
| Q4 24 | -11.0% | -103.6% | ||
| Q3 24 | -4.8% | -131.2% | ||
| Q2 24 | 1.3% | -110.9% | ||
| Q1 24 | -5.2% | -544.4% |
每股收益（稀释后）EBRYTM
| Q4 25 | $-0.08 | $-0.73 | ||
| Q3 25 | $0.06 | $-0.82 | ||
| Q2 25 | $-0.02 | $-0.75 | ||
| Q1 25 | $-0.07 | $-0.81 | ||
| Q4 24 | $-0.09 | $-0.71 | ||
| Q3 24 | $-0.04 | $-0.73 | ||
| Q2 24 | $0.01 | $-0.55 | ||
| Q1 24 | $-0.05 | $-2.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.9M | $388.9M |
| 总债务越低越好 | $144.4M | — |
| 股东权益账面价值 | $179.1M | $139.1M |
| 总资产 | $647.2M | $480.2M |
| 负债/权益比越低杠杆越低 | 0.81× | — |
8季度趋势，按日历期对齐
现金及短期投资EBRYTM
| Q4 25 | $299.9M | $388.9M | ||
| Q3 25 | — | $416.1M | ||
| Q2 25 | — | $291.0M | ||
| Q1 25 | — | $314.5M | ||
| Q4 24 | $441.5M | $320.6M | ||
| Q3 24 | $24.7M | $298.4M | ||
| Q2 24 | $56.7M | $319.1M | ||
| Q1 24 | $113.7M | $201.2M |
总债务EBRYTM
| Q4 25 | $144.4M | — | ||
| Q3 25 | $174.9M | — | ||
| Q2 25 | $241.3M | — | ||
| Q1 25 | $241.0M | — | ||
| Q4 24 | $240.7M | — | ||
| Q3 24 | $240.4M | — | ||
| Q2 24 | $358.7M | — | ||
| Q1 24 | $358.2M | — |
股东权益EBRYTM
| Q4 25 | $179.1M | $139.1M | ||
| Q3 25 | $189.1M | $148.8M | ||
| Q2 25 | $177.2M | $-11.9M | ||
| Q1 25 | $173.3M | $18.9M | ||
| Q4 24 | $170.2M | $21.7M | ||
| Q3 24 | $179.8M | $11.2M | ||
| Q2 24 | $176.2M | $39.3M | ||
| Q1 24 | $184.1M | $61.6M |
总资产EBRYTM
| Q4 25 | $647.2M | $480.2M | ||
| Q3 25 | $744.6M | $506.9M | ||
| Q2 25 | $784.1M | $372.7M | ||
| Q1 25 | $812.3M | $386.7M | ||
| Q4 24 | $752.3M | $392.3M | ||
| Q3 24 | $817.4M | $363.6M | ||
| Q2 24 | $894.5M | $381.8M | ||
| Q1 24 | $952.2M | $258.7M |
负债/权益比EBRYTM
| Q4 25 | 0.81× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 2.04× | — | ||
| Q1 24 | 1.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-60.8M | $-25.4M |
| 自由现金流经营现金流 - 资本支出 | $-60.9M | — |
| 自由现金流率自由现金流/营收 | -82.8% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $17.6M | — |
8季度趋势，按日历期对齐
经营现金流EBRYTM
| Q4 25 | $-60.8M | $-25.4M | ||
| Q3 25 | $36.7M | $-26.6M | ||
| Q2 25 | $-17.5M | $-23.3M | ||
| Q1 25 | $59.4M | $-40.4M | ||
| Q4 24 | $-45.3M | $-18.8M | ||
| Q3 24 | $44.6M | $-25.2M | ||
| Q2 24 | $-32.3M | $-29.1M | ||
| Q1 24 | $68.6M | $-40.7M |
自由现金流EBRYTM
| Q4 25 | $-60.9M | — | ||
| Q3 25 | $36.6M | — | ||
| Q2 25 | $-17.5M | — | ||
| Q1 25 | $59.4M | — | ||
| Q4 24 | $-45.3M | — | ||
| Q3 24 | $44.4M | — | ||
| Q2 24 | $-32.4M | — | ||
| Q1 24 | $68.2M | — |
自由现金流率EBRYTM
| Q4 25 | -82.8% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | -24.1% | — | ||
| Q1 25 | 80.4% | — | ||
| Q4 24 | -59.2% | — | ||
| Q3 24 | 57.1% | — | ||
| Q2 24 | -38.3% | — | ||
| Q1 24 | 79.1% | — |
资本支出强度EBRYTM
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.4% | — |
现金转化率EBRYTM
| Q4 25 | — | — | ||
| Q3 25 | 5.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -30.37× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
RYTM
暂无分部数据
